SEC Form 4 · accession 0001140361-16-058361
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William T. Symonds
Officer — Chief Development Officer
Period of report
Mar 15, 2016
Accepted (ET)
Mar 17, 2016 · 8:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Executive Stock Option (Right to Buy)F1 | $3.94 | Mar 15, 2016 | A | 25,000 | A | — | Mar 15, 2026 | Common Shares | 25,000 | 25,000 | D |
Explanation of responses
- F1The options vest as follows: 1/3 on March 15, 2017; 1/3 on March 15, 2018; and 1/3 on March 15, 2019.
Remarks
Attachment: Exhibit 24.1 Power of Attorney